Epoetin theta launched

Eporatio (epoetin theta) has been launched by Ratiopharm for the treatment of symptomatic anaemia in adults with chronic renal failure and in those receiving chemotherapy for non-myeloid malignancies. It is supplied as prefilled syringes in a range of doses from 1000IU to 30,000IU.

View Eporatio drug record

Further information: Ratiopharm

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more